2 December 2021 (Thursday) - Transfusion News Update

The nice people at Transfusion News sent their update today. Three articles… I wish I could get my head round weak D and D variants…

 Daprodustat is Noninferior to Erythropoiesis-Stimulating Agents for Patients with Chronic Kidney Disease Undergoing Dialysis

Transfusion News Image 1
December 1, 2021
According to the U.S. CDC, about 37 million adults in the United States have chronic kidney disease (CKD). As CKD progresses, many patients require dialysis and develop anemia, which is usually treated with blood transfusions, erythropoiesis-stimulating agents (ESAs), and intravenous iron. Previous clinical trials have linked ESA use, however, to increased risk of stroke, myocardial infarction, thrombosis, and even death when targeting a normal hemoglobin level (i.e., 13.0 to 14.0 g/dL). [Read More]
Join us to learn the basics in RHD genetics and biochemistry
Transfusion News Image 1
In this new Transfusion Science Webinar, Sue Johnson, Director of Clinical Education at Versiti and Director of the Transfusion Medicine Program at Marquette University, will share the challenges faced by laboratory scientists in typing for RhD and discuss strategies for detecting and identifying weak and partial D variants. [Register Now]

X- and Gamma-Irradiation Impact Red Blood Cells Similarly
Transfusion News Image 1
November 22, 2021
Transfusion-associated graft versus host disease (TA-GVHD) is a rare complication that occurs when histoincompatible viable lymphocytes are transfused into an immunocompromised individual. The transfused lymphocytes recognize the recipient as foreign and mount an almost universally fatal immunological response. Leukoreduction filters are not completely effective at eliminating TA-GVHD; therefore, red blood cell components are irradiated to prevent TA-GVHD. [Register Now]

No comments:

Post a Comment